Ocular Allergy Treatment May Require Multi-Specialty Collaboration

Written by The Life Science Feed Editorial Team · Published 19 June 2026 · Edited by Mara Voss

> Ocular allergy presents a spectrum of conditions, from mild seasonal conjunctivitis to severe forms like vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC), which can threaten vision. While many cases respond to topical therapies, refractory or complex presentations highlight a clinical dilemma: when does standard ophthalmic care require input from other specialties? The immediate takeaway is that persistent or severe ocular allergy warrants a collaborative approach, integrating expertise from cornea specialists and allergy/asthma physicians to optimise patient outcomes.

KEY TAKEAWAYS

- The Pivot: Recognition that complex ocular allergy is often a manifestation of systemic atopy, requiring a broader management strategy beyond topical ophthalmic agents.
- The Data: No specific trial data provided; emphasis is on established medical knowledge regarding multidisciplinary care.
- The Action: Clinicians should consider referral to or consultation with allergy/asthma specialists for patients with severe, chronic, or refractory ocular allergy, especially those with comorbid systemic atopic conditions.

Ocular allergy encompasses a range of inflammatory conditions affecting the conjunctiva and cornea, driven by hypersensitivity reactions. The most common forms, seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC), are typically managed with topical antihistamines, mast cell stabilisers, or dual-action agents. For more severe presentations, such as VKC and AKC, the inflammatory cascade can lead to significant ocular surface damage, including corneal shield ulcers, limbal stem cell deficiency, and vision impairment. These severe forms are frequently associated with systemic atopic diseases, including asthma, atopic dermatitis, and allergic rhinitis.

The management of ocular allergy traditionally falls within ophthalmology. However, the systemic nature of atopy suggests that a purely localised approach may be insufficient for patients with severe or recalcitrant disease. For instance, patients with AKC often have a history of severe atopic dermatitis, and their ocular symptoms may correlate with the activity of their systemic disease. Similarly, VKC, while often self-limiting by adulthood, can cause significant morbidity during childhood and adolescence, necessitating aggressive anti-inflammatory strategies.

Multidisciplinary Approach to Complex Ocular Allergy

When initial topical ophthalmic treatments, such as corticosteroids or calcineurin inhibitors, fail to control inflammation or when their long-term use is limited by side effects, a re-evaluation of the treatment strategy is indicated. This is where collaboration with other specialists becomes pertinent. Cornea specialists, for example, possess expertise in managing

complex ocular surface diseases, including the diagnosis and treatment of corneal complications arising from severe allergic inflammation. Their involvement can be critical in preserving vision and managing sequelae like corneal scarring or neovascularisation.

Furthermore, the involvement of an allergy/asthma specialist can provide a comprehensive assessment of the patient's systemic allergic profile. This may include identifying specific allergens through skin prick testing or serum IgE assays, which can inform environmental control measures or allergen-specific immunotherapy. Immunotherapy, while not a primary ophthalmic treatment, can modulate the underlying allergic response, potentially reducing the frequency and severity of ocular allergic episodes. For patients with concomitant asthma or severe allergic rhinitis, optimising their systemic allergy management can have a beneficial impact on their ocular symptoms. Systemic immunosuppressants or biologics, typically prescribed by allergists or immunologists, may be considered in severe, refractory cases of ocular allergy that do not respond to conventional topical therapies.

The decision to involve additional specialists should be guided by the severity and chronicity of the ocular allergy, the presence of vision-threatening complications, and the patient's systemic atopic burden. A coordinated approach ensures that all aspects of the patient's allergic disease are addressed, leading to more effective symptom control and prevention of long-term ocular damage. This integrated care model acknowledges that ocular allergy is often a component of a broader systemic condition, requiring a holistic management strategy.

The epidemiology of ocular allergy highlights its widespread impact. SAC and PAC affect a substantial portion of the global population, with prevalence rates varying geographically and often correlating with pollen seasons or exposure to perennial allergens like dust mites and pet dander. While SAC and PAC primarily cause discomfort and reduce quality of life, VKC and AKC, though less common, carry a higher risk of severe ocular morbidity. VKC predominantly affects young males in warm, dry climates, often presenting with giant papillae on the tarsal conjunctiva, corneal punctate epithelial erosions, and sometimes shield ulcers. AKC, conversely, typically affects older individuals with a history of severe atopic dermatitis, manifesting with chronic blepharitis, conjunctival scarring, and persistent epithelial defects.

The underlying mechanism of action for many topical treatments involves targeting histamine receptors or stabilising mast cells to prevent the release of inflammatory mediators. Dual-action agents combine these mechanisms, offering both immediate symptom relief and prophylactic effects. For more severe cases, topical corticosteroids suppress the broader inflammatory response, but their long-term use carries risks such as elevated intraocular pressure and cataract formation. Topical calcineurin inhibitors, like cyclosporine and tacrolimus, modulate T-cell activity, reducing inflammation with a more favorable long-term safety profile for the ocular surface. However, their efficacy can be variable, and some patients remain refractory.

Limitations of a purely ophthalmic approach become evident when considering the systemic nature of atopy. Without addressing the systemic allergic load, ocular symptoms may recur or persist despite aggressive topical therapy. Furthermore, patient adherence to complex topical regimens can be challenging, particularly in pediatric populations affected by VKC. The financial burden of long-term topical medications also represents a significant consideration for many patients. A multidisciplinary approach can help mitigate these limitations by offering alternative or complementary systemic treatments and by providing a more comprehensive understanding of the patient's overall allergic disease, potentially leading to more sustainable and effective management strategies.

CLINICAL IMPLICATIONS

The persistent focus on topical ophthalmic solutions for all forms of ocular allergy, even severe ones, overlooks the systemic nature of atopy. General practitioners and ophthalmologists should recognise that a significant proportion of patients with severe or refractory ocular allergy will have concomitant systemic atopic conditions. Referring these patients to an allergy/asthma specialist is not an admission of failure, but rather an acknowledgement of the complex pathophysiology at play. This collaborative approach can lead to a more accurate diagnosis of specific allergens, better systemic control of allergic inflammation, and potentially a reduction in the need for chronic, high-dose topical corticosteroids.

From an industry perspective, the development of novel topical agents for ocular allergy continues, but the market may benefit from greater emphasis on systemic therapies for severe cases. Biologics, for example, have revolutionised the treatment of severe asthma and atopic dermatitis; their potential role in severe ocular allergy, particularly AKC, warrants further investigation and perhaps dedicated clinical trials. Companies developing these systemic agents should consider the ocular manifestations of atopy as a relevant endpoint, fostering a more integrated approach to patient care.

Ultimately, patients with chronic, debilitating ocular allergy stand to gain the most from this multidisciplinary strategy. Improved symptom control, reduced risk of vision-threatening complications, and a better quality of life are achievable when their care extends beyond a single specialty. It is incumbent upon clinicians to educate patients on the systemic links of their condition and the potential benefits of involving an allergist, ensuring that all avenues for effective management are explored.

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Leonardi A, et al. Allergic Conjunctivitis Management: Update on Ophthalmic Solutions. Curr Allergy Asthma Rep. 2024;24(7):347-360. doi:10.1007/s11882-024-01150-0
2. 2. Roberts G, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798. doi:10.1111/all.13317
3. 3. Jabbehdari S, et al. Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis. Ocul Surf. 2019;17(2):303-309. doi:10.1016/j.jtos.2018.12.002
4. 4. Guglielmetti S, et al. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2010;10(5):478-85. doi:10.1097/ACI.0b013e32833e16e4
5. 5. Ghiglioni DG, et al. Vernal keratoconjunctivitis: An update. Eur J Ophthalmol. 2021;31(6):2828-2842. doi:10.1177/11206721211022153
6. 6. Cornish KS, et al. Systemic cyclosporin A in severe atopic keratoconjunctivitis. Eur J Ophthalmol. 2010;20(5):844-51. doi:10.1177/112067211002000506
7. 7. Alghamdi AH. Clinical applications of tacrolimus in the treatment of ocular diseases: a narrative literature review. Int Ophthalmol. 2025;46(1):1. doi:10.1007/s10792-025-03844-4

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

thelifesciencefeed.com

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed